USPTO serial 90381096
ALIMENTIV
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 8, 2022
- Examiner
- YOUNG, CARRIE SKYE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ALIMENTIV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
London, Ontario, CA
London, Ontario, CA
London, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kathryn E. Garipay
Kathryn E. Garipay OLSON & CEPURITIS, LTD.20 NORTH WACKER DRIVE36TH FLOORCHICAGO, IL 60606Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Computers, peripheral hardware components, namely, blank external hard drives, blank flash drives, and video cables; video capture devices, namely, signal processors, video receivers and video recorders for converting signals from endoscopy machines to USB for storing on computers; Recorded video recording software, and downloadable video recording software configured according to study protocol requirements for receiving, storing and securely sending clinical study data, obtained from using imaging endoscopic procedures, over the Internet to a secure website | ACTIVE | Oct 21, 2020 |
| 035 | Business project management services, namely, project management of clinical studies, recruitment and selection of clinical study sites and investigators, management of clinical study sites and clinical monitoring, managing relationships between vendors and subcontractors, organization and planning of meetings, workshops and events; Records management services, namely, document indexing for others, specifically, coordinating and controlling flow of electronic and paper documents; Data management services for use in pharmaceutical drug development, namely, preparation of Case Report Forms (CRFs), Collection and compilation of information into computer databases in the field of clinical studies; Compilation and provision of statistical and biostatistical information; Medical coding services for others in the nature of coding clinical trial data for purposes of medical science and regulatory review and approvals | ACTIVE | Jun 16, 2020 |
| 042 | Technical writing, namely, medical writing services for developing medical protocols, clinical study reports, investigator brochures, safety reports, informed consent forms, meeting abstracts, posters, manuscripts, study charts, manuals and literature reviews; Providing an Internet website portal featuring clinical study and clinical trial management system tools; Electronic storage of files and documents, secure storage of electronic and paper documents; File sharing services, namely, providing a website featuring technology enabling users to upload and download electronic files, namely, complete and inspection-ready trial management files; Electronic storage services for archiving databases, images and other electronic data in the field of trial management files (TMF), TMF setup, archiving and management of TMP files through lifecycle of clinical study; Conducting scientific research, namely, biostatistics and statistical programming, protocol development of sample size and power calculations, randomization schedules, statistical analysis plans, statistical programming and validation in statistical analysis system, statistical analyses, interpretation and reporting of data for clinical trial reports and publications, statistical and strategic consulting for product development, interim analysis for early decision-making, database integration, New Drug Application (NDA) ready data listings, regulatory submission compliant datasets, thought leadership and operational experience with study data tabulation model and analysis data model regulatory submission standards, integrated safety and efficacy summaries, adaptive design consulting and simulation support, translational research support data monitoring board management and support; Medical research services, namely, medical monitoring and investigator site monitoring in the field of medical review of clinical study materials, preparation of medical monitoring and safety plans, continuous trial oversight via patient level and safety data review, subject eligibility support for investigators, medical support to sites and study teams for interpretation of study protocol, consultation on potential safety issues and medical concerns and 24/7 medical monitor coverage; Pharmaceutical drug development services in the field of drug safety, specifically, processing adverse events from clinical trials, preparing Development Safety Update Reports (DSURs) and other aggregate reports, performing signal detection and benefit-risk assessments, preparing safety management plans and preparing medical monitoring plans; Providing quality assurance services in the field of clinical trials, namely, quality assistance documentation, such as Standard Operating Procedures (SOPs) and work instructions, internal system reviews, site audits, vendor assessments; Medical research services in the field of pharmacology, namely, dose simulation, selection and optimization, selection of biomarkers and endpoints, optimization of trial design, population pharmacokinetic and pharmacodynamic modeling, exposure response modeling; Medical research services in the field of translational medicine, namely, immunohistochemistry, flow cytometry, transcriptomics, proteomics, microbiome study; Providing medical and scientific research information in the field of clinical trials, namely, the design of clinical trials and outcome measures for studying human diseases, or for studying or testing drugs, devices or methods of medical treatment on humans in relation to diseases; Conducting clinical trials for others which study human diseases, or study or test drugs, devices or methods of medical treatment on humans in relation to diseases; Custom computer programming of imaging adjudication and computer systems integration of eligibility data with Interactive Response Technology (IRT); Computer database design and implementation for data collection, data storage, data management, data analysis, and data validation for use in pharmaceutical drug development; Compilation and provision of clinical study data, namely, compiling data for research purposes in the field of medical science and medical consultancy | ACTIVE | Jun 16, 2020 |
| 044 | Medical imaging services; Medical diagnostic testing, monitoring and reporting services; Medical imaging services, namely, electronic medical imaging support services for use in assessing patient health in clinical trials, namely, reviewing and scoring electronic medical images, including video images, of patients supplied by others; Medical imaging services, namely, histopathology support services for reviewing and scoring tissue sample images provided by others; Consulting services in the field of medical imaging, namely, magnetic resonance support services for reviewing and scoring magnetic resonance images provided by others; Medical services, namely, endoscopy support services in the field of reviewing and scoring endoscopic images provided by others | ACTIVE | Jun 16, 2020 |
| 045 | Regulatory submission management, namely, assisting others with preparing and filing applications for new drugs with government regulatory bodies, submission planning and life cycle management of clinical trial applications to Competent Authorities, Ethics Committees and Regulatory Agencies, pre-approval submissions, submission of supplements, amendments and variations applications, submission publishing and dossier compilation in electronic common technical document or common technical document formats, annual reports, paper submissions management and submission archival | ACTIVE | Jun 16, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Alimentiv Inc.
- Other trademarks owned by Alimentiv Inc.
- Other trademarks owned by Alimentiv Inc.
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named ALIMENTIV
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 8, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 8, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 23, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 23, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 3, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 16, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 6, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 6, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 6, 2022 | ALIE | ASSIGNED TO LIE | — |
| Jun 21, 2022 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 13, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 13, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 13, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 13, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 13, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 13, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 13, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 19, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 18, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 18, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 7, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 7, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 29, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 28, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 28, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 15, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 4, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 23, 2021 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Feb 22, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 17, 2020 | NWAP | NEW APPLICATION ENTERED | — |